Back to top

Image: Bigstock

Is Immunology Emerging as Eli Lilly's Next Growth Driver?

Read MoreHide Full Article

Key Takeaways

  • Lilly's immunology revenues rose 9.4% to $4.06 billion in the first nine months of 2026.
  • Ebglyss and Omvoh sales surged 87% collectively, reaching $844 million during the period.
  • Acquisitions of DICE, Morphic, Ventyx, Orna and Merida strengthen Lilly's immunology pipeline.

Eli Lilly and Company (LLY - Free Report) continues to derive a significant portion of its revenues from its blockbuster GLP-1 drugs, Mounjaro and Zepbound. However, the company is actively working to diversify its business beyond cardiometabolic treatments. Lilly is investing in immunology through commercial expansion, clinical development and strategic acquisitions to establish additional long-term growth drivers.

The company has built an established immunology portfolio led by Taltz, alongside newer treatments such as Ebglyss and Omvoh. These medicines address chronic inflammatory and autoimmune diseases, including psoriasis, atopic dermatitis, ulcerative colitis and Crohn's disease. Lilly is also pursuing novel therapies targeting inflammatory pathways and developing oral treatments that could provide alternatives to injectable biologics.

Lilly’s Immunology Portfolio Delivers Steady Revenue Growth

Lilly's immunology segment contributed approximately $4.06 billion in revenues during the first nine months of 2026, up 9.4% year over year. This accounted for around 6% of the company's total revenues of $67.2 billion during the period. While considerably smaller, this business provides Lilly with an established commercial platform that could benefit from newer product launches, additional indications and pipeline expansion.

The portfolio comprises Taltz, Ebglyss, Omvoh and Olumiant, with Taltz, an IL-17A inhibitor, remaining the largest contributor, accounting for approximately 60.3% of immunology revenues. Taltz generated $2.4 billion in revenues in the first nine months of 2026, down 2.7% year over year. Meanwhile, Ebglyss and Omvoh are emerging as important growth drivers, collectively generating $844 million in sales in the first nine months of 2026, up around 87% year over year.

Lilly Expands Immunology Pipeline With Promising Candidates

Lilly's Immunology pipeline reflects a move toward oral therapies, novel immune targets and potential combination treatments.

Omvoh (mirikizumab) is being studied in late-stage studies in combination with tirzepatide for ulcerative colitis and Crohn's disease, while Ebglyss (lebrikizumab) is being evaluated in late-stage studies for perennial allergens and chronic rhinosinusitis with nasal polyps (CRSwNP). In its mid-stage pipeline, the company has eltrekibart, a chemokine-targeting antibody being evaluated in hidradenitis suppurativa and ulcerative colitis; simepdekinra (DC-853), an oral IL-17 inhibitor being studied in psoriasis; and zotemtegrast, an oral α4β7 integrin inhibitor acquired through the Morphic acquisition, in ulcerative colitis and Crohn's disease.

Interestingly, Lilly is also seeking to extend the potential applications of its incretin expertise beyond obesity and diabetes into gastrointestinal disorders. The company has initiated two phase II studies of brenipatide, its GIP/GLP-1 dual agonist, in irritable bowel syndrome, evaluating the candidate separately in patients with IBS with constipation and IBS with diarrhea.

Strategic Acquisitions Bolster Lilly's Immunology Franchise

Lilly has aggressively pursued acquisitions to strengthen its immunology pipeline and broaden its technological capabilities. These transactions have expanded the company's research efforts beyond conventional injectable biologics into oral anti-inflammatory medicines, precision immunotherapies and next-generation cell therapies.

The $2.4 billion acquisition of DICE Therapeutics, completed in 2023, added oral IL-17 inhibitors and an oral α4β7 integrin program to Lilly's portfolio. The 2024 acquisition of Morphic Holding added MORF-057 (now zotemtegrast), an oral α4β7 integrin inhibitor, further strengthening Lilly's IBD pipeline. In 2026, Lilly acquired Ventyx Biosciences for $1.2 billion, gaining access to NLRP3 inhibitors, and Orna Therapeutics for up to $2.4 billion, adding innovative in vivo CAR-T technology for autoimmune diseases. Its October 2026 acquisition of Merida Biosciences for up to $2.9 billion further strengthened its precision immunology capabilities.

Conclusion — Immunology as a Future Growth Driver

Lilly is steadily transforming its immunology operations from a business heavily reliant on Taltz into a broader franchise supported by emerging commercial drugs and a diversified development pipeline. Ebglyss and Omvoh are already contributing meaningful growth, while the acquisitions of DICE, Morphic, Ventyx, Orna and Merida have strengthened the company's capabilities in developing novel immune-targeted medicines.

Although immunology currently accounts for only about 6% of Lilly's total revenues, the company's continued investments demonstrate its commitment to establishing additional growth drivers beyond the blockbuster Mounjaro and Zepbound franchise. The commercial performance of newer medicines, successful development of oral therapies and progression of acquired assets will be important in determining whether immunology becomes a substantially larger contributor to Lilly's revenues over the coming years.

Competition to LLY’s Immunology Products

Lilly faces strong competition across its Immunology portfolio from both established biologics and newer targeted therapies. Taltz competes with IL-17 inhibitors such as Novartis’ (NVS - Free Report) Cosentyx and UCB’s Bimzelx, as well as IL-23 inhibitors and other biologics used in psoriasis and psoriatic arthritis. Ebglyss faces competition from Sanofi/Regeneron’s Dupixent and oral JAK inhibitors such as AbbVie’s (ABBV - Free Report) Rinvoq and Pfizer’s Cibinqo in atopic dermatitis.

Omvoh competes in the highly competitive inflammatory bowel disease or IBD market against products such as AbbVie’s Skyrizi and Rinvoq, Johnson & Johnson’s (JNJ - Free Report) Tremfya and Stelara and Takeda’s Entyvio. Meanwhile, Olumiant competes with other JAK inhibitors and biologics in rheumatoid arthritis, as well as Pfizer’s Litfulo and Sun Pharma’s Leqselvi in alopecia areata.

LLY’s Stock Price, Valuation and Estimates

Lilly’s stock has risen 28.7% so far this year compared with the industry’s increase of 24.2% over the same timeframe.

Zacks Investment ResearchImage Source: Zacks Investment Research

From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 28.25 forward earnings, higher than 19.50 for the industry. However, the stock is trading below its 5-year mean of 34.57.

Zacks Investment ResearchImage Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 has risen from $33.86 to $35.36 per share over the past 30 days, while that for 2027 has risen from $47.13 to $50.71 per share over the same timeframe.

Zacks Investment ResearchImage Source: Zacks Investment Research

Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in